Comprehensive coverage

Copaxone

Clusters of microglial cells (in green) and T cells (in red) in the brain of a mouse with MS-like disease (left: general view, right: close-up)

Deaf people with sclerosis

The scientists of the institute have identified the cells in the brain that are responsible for the grace periods of the multiple sclerosis patients. The findings may pave the way for new treatments
Prof. Ruth Arnon, from Magali Copaxon, and the president of the National Academy of Sciences. Photo: Courtesy of the National Academy of Sciences

New President of the Israel National Academy of Sciences: Prof. Ruth Arnon

  • One response
Copaxone syringe

The cumulative scope of treatment with Copaxone for the treatment of multiple sclerosis has reached one million patient-years

  • No comments

Copaxone is also approved by the FDA for the treatment of patients after a first clinical event that may indicate multiple sclerosis

  • One response

A journey in the Land of Lemma * About Prof. Ruth Arnon, the co-discoverer of Copaxone

  • One response
Science website logo
SEARCH